A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week

NCT ID: NCT03723772

Last Updated: 2025-03-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 66 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-11-29
• Study Completion Date: 2020-06-26

Brief Summary

This study compares the new long-acting insulin 287 with the marketed insulin glargine for use in type 1 diabetes. The study will test how insulin is taken up in your blood, how long it stays there and how the blood sugar is lowered. The participant will get both of the insulins in a random order. Insulin 287 is a new medicine while insulin glargine is already approved for the treatment of diabetes and can be prescribed by a doctor. The participant will get 8 weekly doses of insulin 287 and 14 daily doses of insulin glargine. There will also be a run-in period of 2 days to 4 weeks with daily doses of insulin glargine before you start the insulin 287 period. All doses will be injected under the skin. The study will last for about 16 to 24 weeks. The participant will have 27 visits with the study doctor.

Conditions

Diabetes Mellitus, Type 1

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Insulin 287 followed by insulin glargine U100

Run-in period (2 days to 4 weeks): The basal insulin glargine dose for each subject will be established and optimised.

After run-in, participants will receive insulin 287 once a week (OW) for 8 weeks and subsequent 4 weeks of terminal pharmacokinetic sampling where subjects are treated with once daily (OD) insulin glargine.

After insulin 287 treatment, participants will receive insulin glargine U100 OD for 2 weeks.

Group Type: EXPERIMENTAL

Insulin icodec

Intervention Type: DRUG

Participants will receive subcutaneous injections of insulin 287 once weekly for 8 weeks

IGlar U100

Intervention Type: DRUG

Participants will receive subcutaneous injections of insulin glargine once weekly for 2 weeks.

Insulin glargine U100 followed by insulin 287

Run-in period (2 days to 4 weeks): The basal insulin glargine dose for each subject will be established and optimised.

After run-in, participants will receive insulin glargine U100 OD for 2 weeks followed by 1-14 days (at least 1 day is mandatory) of continued insulin glargine treatment.

After insulin glargine treatment, participants will receive insulin 287 once a week (OW) for 8 weeks and subsequent 4 weeks of terminal pharmacokinetic sampling.

Group Type: EXPERIMENTAL

Insulin icodec

Intervention Type: DRUG

Participants will receive subcutaneous injections of insulin 287 once weekly for 8 weeks

IGlar U100

Intervention Type: DRUG

Participants will receive subcutaneous injections of insulin glargine once weekly for 2 weeks.

Interventions

Insulin icodec

Participants will receive subcutaneous injections of insulin 287 once weekly for 8 weeks

Intervention Type: DRUG

IGlar U100

Participants will receive subcutaneous injections of insulin glargine once weekly for 2 weeks.

Intervention Type: DRUG

Other Intervention Names

Insulin 287

Eligibility Criteria

Inclusion Criteria

• Male or female, aged 18-64 years (both inclusive) at the time of signing informed consent
• Diagnosed with type 1 diabetes mellitus greater than or equal to 1 year prior to the day of screening
• Current daily basal insulin treatment greater than or equal to 0.2 U/kg/day
• Body mass index between 18.5 and 29.0 kg/m^2 (both inclusive)
• HbA1c less than or equal to 9.0%

Exclusion Criteria

• History or presence of any clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal or endocrinological conditions. Subjects with complications associated to diabetes can be included only if they are judged to be mild by the investigator. Subjects with other comorbidities (e.g. dyslipidaemia, hypertension and hypothyroidism) can be included if they have a stable treatment and are in adequate control according to the judgement of the investigator- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice)
• Known or suspected hypersensitivity to trial products or related products

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 64 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novo Nordisk A/S

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Reporting Anchor and Disclosure (1452)

Role: STUDY_DIRECTOR

Novo Nordisk A/S

Locations

Profil Institut für Stoffwechselforschung GmbH

Neuss, , Germany

Countries

Germany

References

Hovelmann U, Engberg S, Heise T, Kristensen NR, Norgreen L, Zijlstra E, Ribel-Madsen R. Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes. Diabetes Obes Metab. 2024 May;26(5):1941-1949. doi: 10.1111/dom.15510. Epub 2024 Feb 20.

Reference Type: RESULT

PMID: 38379002 (View on PubMed)

Other Identifiers

U1111-1204-8909

Identifier Type: OTHER

Identifier Source: secondary_id

2017-004528-31

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

NN1436-4225

Identifier Type: -

Identifier Source: org_study_id